Answers are grounded in this paper and cite their sources.
Salmonella infections are a major concern in poultry, impacting both animal health and food safety. Conventional vaccines, including live attenuated and inactivated bacterins, often exhibit limited efficacy and short-lived immunity. This study aims to develop and evaluate a novel oral vaccine formulation incorporating poly-lactide-co-glycolide (PLG) microparticles conjugated with Salmonella Typhimurium outer membrane vesicles (OMVs). PLG microparticles were synthesized using the solvent evaporation technique and characterized for size (3654 ± 914.6 nm) and zeta potential (-12.3 mV). Immunization trials in poultry birds revealed that the PLG-OMV vaccine elicited significantly higher IgG and sIgA responses compared to unadjuvanted OMVs, chitosan nanoparticle-OMVs, and Gantrez® nanoparticle-OMVs. The vaccine also induced robust cellular immunity, with elevated IFN-γ production and CD8 + T-cell activation. Protective challenge studies demonstrated reduced Salmonella Typhimurium fecal shedding and 100% survival against Salmonella Gallinarum infection. These findings highlight PLG-OMV microparticles as a promising strategy for Salmonella control in poultry.
No takes yet. Share an insight, caveat, or question.
Begum et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: